AKAntonis E. Koromilas

Antonis E. Koromilas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonis E. Koromilas has a total of 418 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiomic Analysis of Cachectic Mice Reveals Cancer Driven Suppression of Muscle Differentiation

    by Vahab Soleimani, Darren Blackburn, Aldo Hernández-Corchado, Korin Sahinyan, Hedieh Habibi Khorasani, Felicia Lazure, Vincent Richard, Dianbo Qu, Shuo Wang, Christoph Borchers, et al.

    Cancer cachexia is a severe wasting syndrome characterized by progressive loss of skeletal muscle mass, reduced regenerative capacity, and poor response to cancer therapy. The mechanisms by which tumors directly disrupt muscle stem cell function remain incompletely understood. Using the C26 adenocarcinoma model, we show that tumor cells undergo marked transcriptional adaptation within the host environment and acquire a secretory program that directly reprograms skeletal muscle and muscle stem cells. Multiomic profiling revealed that cachexia is associated with broad transcriptional and epigenetic remodeling of muscle stem cells, including induction of an epithelial-to-mesenchymal transition (EMT)-like program, reduced accessibility at myogenic regulatory factor binding sites, and impaired expression of key differentiation regulators. Mechanistically, exposure to the C26 tumor secretome increased SNAI1, a central EMT regulator, while suppressing MyoD, Myogenin, and MyHC and blocking myogenic differentiation and fusion. Importantly, SNAI1 knockdown rescued myogenic differentiation in the presence of C26-conditioned medium, establishing SNAI1 as a functional mediator of tumor-induced myogenic suppression. Cytokine profiling identified MMP9 as a prominent tumor-derived circulating factor, and pharmacological MMP9 inhibition in tumor-bearing mice preserved the PAX7-positive muscle stem cell pool. In contrast, loss of tumor-derived GDF15 alone was insufficient to rescue cachexia, supporting a multifactorial tumor-secretome model. Together, these findings define a mechanistic axis in which tumor adaptation to the host promotes induction of EMT-like reprogramming in muscle progenitors, suppresses myogenic differentiation, and contributes to regenerative failure and muscle wasting.

  • Open Access

    Integrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolution

    by Shiqi Diao, Jia Yi Zou, Shuo Wang, Jason E. Chan, Roderik M. Kortlever, Nicolas Poulain, Nour Ghaddar, Hyungdong Kim, Gerard I. Evan, Constantinos Koumenis, et al.

    Tumour progression towards dedifferentiated cell clusters plays a critical role in intratumour heterogeneity and therapy resistance. While tumour microenvironmental stress has been implicated, the underlying mechanisms remain poorly defined. Using mouse models of lung adenocarcinoma, we demonstrate that activation of the integrated stress response (ISR)—marked by phosphorylation of eIF2 (p-eIF2) and ATF4 induction—drives tumour heterogeneity. ISR activation facilitates the emergence of high-plasticity, undifferentiated and pre-epithelial-to-mesenchymal transition clusters characterized by elevated ATF4 and MYC activity. This process is MYC dependent and involves ISR-mediated repression of NKX2-1, a key determinant of alveolar identity, and induction of CHCHD10, a regulator of mitochondrial integrity and metabolic fitness. Disruption of the p-eIF2–ATF4 axis induces mitochondrial dysfunction, limits dedifferentiation and suppresses tumour growth. In human lung adenocarcinoma, ISR-driven dedifferentiation correlates with advanced disease and poor prognosis, identifying the ISR as a central driver of lineage reprogramming and metabolic fitness in tumour progression.


  • Open Access

    Pde4 mediates MHCII expression in oligodendroglia

    by Miguel M. Madeira, Zachary Hage, Dimitris Koliatsis, Alexandros G. Kokkosis, Kimberly Nnah, Alexander J. Rhee, Gilbert J. Rahme, Katherine Kamvisios, Antonis E. Koromilas, Barbara Rosati, et al.

    Chronic psychosocial stress is a major precipitant of Major Depressive Disorder (MDD), yet the glial mechanisms that translate sustained stress into maladaptive myelin and immune changes remain unclear. Using chronic social defeat stress and single-nucleus RNA sequencing of anterior medial PFC (mPFC) oligodendroglia, we identified a mature-oligodendrocyte cluster almost exclusively from stress-susceptible animals, marked by immune genes (MHCII) and upregulated Pde4b. Integration with a human MDD single-nucleus RNA sequencing dataset confirmed a conserved immune-like oligodendrocyte (ImOL) subset coexpressing Plp1 and Cd74 and enriched for Pde4b. Mechanistically, PDE4 inhibition with crisaborole elevated cAMP–PKA–CREB signaling, blocked IFNγ-induced MHCII expression, and engaged the eIF2α–ATF4/CHOP arm of the integrated stress response (ISR). In vivo modulation of the ISR with ISRIB or guanabenz bidirectionally controlled ImOL prevalence and stress-related behaviors. These findings position Pde4b–cAMP–ISR signaling as a regulator of oligodendroglial immune phenotypes and a promising target to modulate myelination and neuroinflammation in stress-related disorders.

  • Open Access

    eIF2B Selectively Anchors and Activates Mutant KRAS

    by Hyungdong Kim, Shiqi Diao, Kwang-Jin Cho, Hyun-Ro Lee, Junchen Liu, Pascal Egea, Tatu Pantsar, Milla Kurki, Nour Ghaddar, Shuo Wang, et al.

    Much is known about how RAS oncoproteins regulate mRNA translation factors, but the reverse relationship, how translation factors influence RAS activity, has remained largely unexplored. At the plasma membrane (PM), Son of Sevenless (SOS) acts as the canonical guanine nucleotide exchange factor (GEF) for RAS proteins, yet mechanisms governing its specificity for individual RAS isoforms remain unknown. Here, we show that the translation initiation factor eIF2B, best known for its GEF function in translation initiation, forms a distinct complex with SOS and mutant KRAS at the PM, but not with other oncogenic RAS variants. Mechanistically, eIF2B acts as an allosteric regulator of SOS, selectively enhancing GDP–GTP exchange on mutant KRAS. This specificity arises from the translational activity of eIF2B, which upregulates glycosphingolipid (GSL) biosynthesis to remodel PM lipids and preferentially anchor mutant KRAS. Together, our results uncover an unexpected moonlighting function of eIF2B: acting both as a direct activator of SOS and as a regulator of GSL pathway that shapes the membrane landscape, both required for mutant KRAS activation. These insights redefine our understanding of eIF2B and mutant KRAS functions in cancer and have profound implications for KRAS-driven oncogenesis. Graphical eIF2B interacts with mutant KRAS and SOS at the plasma membrane (PM). The eIF2B:SOS complex promotes the GTP-bound active state of mutant KRAS. eIF2B enhances the translation of B4GALT5 mRNA, encoding a key enzyme of glycosphingolipid (GSL) biosynthesis. Upregulation of the GSL metabolites, ganglioside GM3 and sulfatide SM4, remodels PM lipid composition to facilitate eIF2B:SOS:KRAS complex formation and mutant KRAS nanoclustering. Through its interaction with SOS and stimulation of GSL synthesis, eIF2B selectively activates mutant KRAS at the PM among RAS isoforms. eIF2B is required for the development of mKRAS-driven lung adenocarcinoma in mice. eIF2B is a marker of poor prognosis in mutant KRAS-driven cancers.

  • Open Access

    A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer

    by Shuo Wang, Shiqi Diao, Hyungdong Kim, Jia Yi Zou, Ke Ke Li, Antonis E. Koromilas

    In tumorous conditions, STAT1, traditionally recognized for its anti-tumor role in immunology, exhibits pro-survival characteristics, though unclear mechanisms. Investigating STAT1 function in isogenic colorectal tumor cells with wild-type or mutant KRAS, we found that STAT1 specifically promotes tumor survival and proliferation with mutant KRAS. Gene expression profiling revealed that STAT1 promotes the expression of sterol and lipid biosynthesis genes in these cells. This effect depends on STAT1 phosphorylation at S727, which upregulates SREBP1 and SREBP2 to drive de novo lipid production. In mutant KRAS cells, STAT1 amplifies the mevalonate pathway, maintaining its S727 phosphorylation and establishing a positive feedback loop through the transcription factors YAP1 and TEAD4, further driving lipid biosynthesis and tumor growth. This STAT1-YAP1 axis promotes mutant KRAS tumor cells’ resistance to mevalonate pathway inhibitors, which can be overcome by pharmacologically targeting the YAP1-TEAD interaction. Moreover, this axis contributes to the inherent resistance of mutant KRAS colon cancer cells to EGFR-targeted therapy. Together, these findings identify the STAT1-YAP1 pathway as a critical mediator of therapy resistance and a promising therapeutic target in mutant KRAS colorectal cancer.


  • Open Access

    Plasticity of the mammalian integrated stress response

    by Chien-Wen Chen, David Papadopoli, Krzysztof J. Szkop, Bo-Jhih Guan, Mohammed Alzahrani, Jing Wu, Raul Jobava, Mais M. Asraf, Dawid Krokowski, Anastasios Vourekas, et al.

    An increased level of phosphorylation of eukaryotic translation initiation factor 2 subunit-α (eIF2α, encoded by EIF2S1; eIF2α-p) coupled with decreased guanine nucleotide exchange activity of eIF2B is a hallmark of the ‘canonical’ integrated stress response (c-ISR)1. It is unclear whether impaired eIF2B activity in human diseases including leukodystrophies2, which occurs in the absence of eIF2α-p induction, is synonymous with the c-ISR. Here we describe a mechanism triggered by decreased eIF2B activity, distinct from the c-ISR, which we term the split ISR (s-ISR). The s-ISR is characterized by translational and transcriptional programs that are different from those observed in the c-ISR. Opposite to the c-ISR, the s-ISR requires eIF4E-dependent translation of the upstream open reading frame 1 and subsequent stabilization of ATF4 mRNA. This is followed by altered expression of a subset of metabolic genes (for example, PCK2), resulting in metabolic rewiring required to maintain cellular bioenergetics when eIF2B activity is attenuated. Overall, these data demonstrate a plasticity of the mammalian ISR, whereby the loss of eIF2B activity in the absence of eIF2α-p induction activates the eIF4E–ATF4–PCK2 axis to maintain energy homeostasis.


  • Open Access

    Lineage plasticity of the integrated stress response is a hallmark of cancer evolution

    by Shiqi Diao, Jia Yi Zou, Shuo Wang, Nour Ghaddar, Jason E. Chan, Hyungdong Kim, Nicolas Poulain, Constantinos Koumenis, Maria Hatzoglou, Peter Walter, et al.

    The link between the “stress phenotype”-a well-established hallmark of cancer-and its role in tumor progression and intratumor heterogeneity remains poorly defined. The integrated stress response (ISR) is a key adaptive pathway that enables tumor survival under oncogenic stress. While ISR has been implicated in promoting tumor growth, its precise role in driving tumor evolution and heterogeneity has not been elucidated. In this study, using a genetically engineered mouse models, we demonstrate that ISR activation—indicated by elevated levels of phosphorylated eIF2 (p-eIF2) and ATF4—is essential for the emergence of dedifferentiated, therapy-resistant cell states. ISR, through the coordinated actions of ATF4 and MYC, facilitates the development of tumor cell populations characterized by high plasticity, stemness, and an epithelial-mesenchymal transition (EMT)-prone phenotype. This process is driven by ISR-mediated expression of genes that maintain mitochondrial integrity and function, critical for sustaining tumor progression. Importantly, genetic, or pharmacological inhibition of the p-eIF2–ATF4 signaling axis leads to mitochondrial dysfunction and significantly impairs tumor growth in mouse models of lung adenocarcinoma (LUAD). Moreover, ISR-driven dedifferentiation is associated with poor prognosis and therapy resistance in advanced human LUAD, underscoring ISR inhibition as a promising therapeutic strategy to disrupt tumor evolution and counteract disease progression.


  • Open Access

    A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer

    by Shuo Wang, Shiqi Diao, Hyungdong Kim, Jia Yi Zou, Ke Ke Li, Antonis E. Koromilas

    In tumorous conditions, the transcription factor STAT1, traditionally recognized for its anti-tumor role in immunology, exhibits pro-survival characteristics, though the underlying mechanisms remain unclear. Investigating STAT1’s function in isogenic colorectal tumor cells with wild-type or mutant KRAS, we found that STAT1 specifically promotes the survival and proliferation of cells with mutant KRAS. Through gene expression profiling, we discovered a previously unknown role of STAT1 in upregulating sterol and lipid biosynthetic genes specifically in mutant KRAS cells. This effect is driven by STAT1’s phosphorylation at serine 727 and its cooperation with STAT3 and STAT5 for the transcriptional upregulation of sterol regulatory element-binding proteins (SREBP) 1 and 2, which boost de novo sterol and lipid biosynthesis. In mutant KRAS cells, STAT1 amplifies the mevalonate pathway, maintaining its serine 727 phosphorylation through RHO GTPase signaling and establishing a positive feedback loop through the transcription factors YAP1 and TEAD4, further driving lipid biosynthesis and tumor growth. Through xenograft tumor assays in mice, we discovered that the STAT1-YAP1 axis plays a role in mutant KRAS tumor cells’ resistance to mevalonate pathway inhibitors, which can be overcome by pharmacologically targeting the YAP1-TEAD interaction. Additionally, the STAT1-YAP1 arm is essential for the intrinsic resistance to EGFR-targeting therapy in the mutant KRAS colon cancer cells. These findings indicate that the STAT1-YAP1 pathway plays a significant role in therapy resistance and presents a potential therapeutic target in mutant KRAS colorectal cancer.


  • Open Access

    A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer

    by Regina Cencic, Young K. Im, Sai Kiran Naineni, Mohamed Moustafa-Kamal, Predrag Jovanovic, Valerie Sabourin, Matthew G. Annis, Francis Robert, T. Martin Schmeing, Antonis Koromilas, et al.

    In this study, we aimed to address the current limitations of therapies for macro-metastatic triple-negative breast cancer (TNBC) and provide a therapeutic lead that overcomes the high degree of heterogeneity associated with this disease. Specifically, we focused on well-documented but clinically underexploited cancer-fueling perturbations in mRNA translation as a potential therapeutic vulnerability. We therefore developed an orally bioavailable rocaglate-based molecule, MG-002, which hinders ribosome recruitment and scanning via unscheduled and non-productive RNA clamping by the eukaryotic translation initiation factor (eIF) 4A RNA helicase. We demonstrate that MG-002 potently inhibits mRNA translation and primary TNBC tumor growth without causing overt toxicity in mice. Importantly, given that metastatic spread is a major cause of mortality in TNBC, we show that MG-002 attenuates metastasis in pre-clinical models. We report on MG-002, a rocaglate that shows superior properties relative to existing eIF4A inhibitors in pre-clinical models. Our study also paves the way for future clinical trials exploring the potential of MG-002 in TNBC and other oncological indications.


  • Open Access

    SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis

    by Dibyendu K. Panda, Xiuying Bai, Yan Zhang, Nicholas A. Stylianesis, Antonis E. Koromilas, Mark L. Lipman, Andrew C. Karaplis

    The Hippo pathway nuclear effector Yes-associated protein (YAP) potentiates the progression of polycystic kidney disease (PKD) arising from ciliopathies. The mechanisms underlying the increase in YAP expression and transcriptional activity in PKD remain obscure. We observed that in kidneys from mice with juvenile cystic kidney (jck) ciliopathy, the aberrant hyperactivity of mechanistic target of rapamycin complex 1 (mTORC1), driven by ERK1/2 and PI3K/AKT cascades, induced ER proteotoxic stress. To reduce this stress by reprogramming translation, the protein kinase R–like ER kinase–eukaryotic initiation factor 2α (PERK/eIF2α) arm of the integrated stress response (ISR) was activated. PERK-mediated phosphorylation of eIF2α drove the selective translation of activating transcription factor 4 (ATF4), potentiating YAP expression. In parallel, YAP underwent K63-linked polyubiquitination by SCF S-phase kinase-associated protein 2 (SKP2) E3 ubiquitin ligase, a Hippo-independent, nonproteolytic ubiquitination that enhances YAP nuclear trafficking and transcriptional activity in cancer cells. Defective ISR cellular adaptation to ER stress in eIF2α phosphorylation–deficient jck mice further augmented YAP-mediated transcriptional activity and renal cyst growth. Conversely, pharmacological tuning down of ER stress/ISR activity and SKP2 expression in jck mice by administration of tauroursodeoxycholic acid (TUDCA) or tolvaptan impeded these processes. Restoring ER homeostasis and/or interfering with the SKP2-YAP interaction represent potential therapeutic avenues for stemming the progression of renal cystogenesis.